10-Q: Establishment Labs Reports Q3 2024 Results, Revenue Declines Amidst Macroeconomic Headwinds

Establishment Labs reported a decrease in revenue for the nine months ended September 30, 2024, alongside a net loss, while highlighting FDA approval for Motiva Implants and a new manufacturing facility.

Summary

• Establishment Labs reported a revenue of $121.5 million for the nine months ended September 30, 2024, a decrease of 9.1% compared to the same period in 2023.
• The company experienced a net loss of $50.1 million for the nine months ended September 30, 2024, compared to a net loss of $58.0 million for the same period in 2023.
• As of September 30, 2024, the company had an accumulated deficit of $410.2 million and a cash balance of $39.7 million.
• The company received FDA approval for its Motiva Implants in September 2024 and began selling them in the United States in October 2024.
• A new manufacturing facility in Costa Rica was completed in June 2024, increasing manufacturing capacity by approximately 730,000 units per year.
• The company completed a registered direct offering of common shares and pre-funded warrants in November 2024, generating approximately $50 million in gross proceeds.
• The company also amended its credit agreement in November 2024, extending the commitment termination date for the Tranche D Term Loans.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company achieved FDA approval and completed a new facility, revenue declined and losses persist. The capital raise is a positive, but the material weakness and reliance on a single supplier are concerning.

Positives

• FDA approval for Motiva Implants in the U.S. market is a significant milestone for the company.
• The completion of the new manufacturing facility in Costa Rica increases production capacity.
• The company successfully raised $50 million in gross proceeds through a registered direct offering.
• The net loss improved compared to the same period in the previous year.
• The company has expanded its medical training programs, completing 192 sessions in 2023.

Negatives

• Revenue decreased by 9.1% for the nine months ended September 30, 2024, compared to the same period in 2023.
• The company continues to incur net losses, with an accumulated deficit of $410.2 million as of September 30, 2024.
• The company's cash balance decreased slightly to $39.7 million as of September 30, 2024.
• The company relies on a single-source supplier for medical-grade silicone, which poses a risk to its supply chain.
• The company has identified a material weakness in its internal control over financial reporting related to change management controls.

Risks

• The company faces risks related to unfavorable global economic conditions, including slower growth, recession, and inflation.
• The company's ability to achieve and maintain profitability depends on the commercial success of Motiva Implants.
• The company may need to raise additional capital, which may not be available on acceptable terms.
• The company faces competition from larger companies with greater resources.
• The company is exposed to risks associated with operating in emerging markets.
• The company is subject to risks related to product liability claims and negative publicity.
• The company relies on a single-source supplier for medical-grade silicone.
• The company is subject to risks related to cybersecurity incidents and data breaches.
• The company is subject to extensive and evolving medical device regulations.
• The company is subject to risks related to tax law changes and potential disagreements with tax authorities.

Future Outlook

The company expects higher selling prices in the United States and the introduction of new products to positively impact gross margins in 2025. The company also anticipates an increase in operating expenses following the FDA approval of Motiva Implants.

Management Comments

• Demand in fiscal 2024 improved from the second half of fiscal 2023.
• Latin America, Brazil in particular, which remains our largest single market, continues to suffer from weaker underlying demand for aesthetic and reconstructive plastic surgery as compared to fiscal 2023.
• We expect higher selling prices in the United States and the introduction of other new products will positively impact gross margins in 2025.
• While we are still very focused on managing operating expenses, our commercial and operational activities will increase following the FDA approval of Motiva Implants.

Industry Context

The announcement comes amidst ongoing scrutiny of the breast implant industry, including concerns about BIA-ALCL and other cancers. The company's focus on safety and innovation is relevant in this context. The company's entry into the US market is a significant development in the competitive landscape.

Comparison to Industry Standards

• The company's post-market surveillance data suggests low rates of adverse events compared to competitors, but this data was not generated in connection with a U.S. FDA pre-market approval study.
• The company's competitors include Sientra, Mentor Worldwide LLC (a division of Johnson & Johnson), and Allergan plc (recently acquired by AbbVie Inc.), all of which have conducted large prospective clinical studies.
• The company's gross margin of 65.0% for the nine months ended September 30, 2024, is within the range of other medical device companies, but may be impacted by geographic mix and pricing strategies.
• The company's reliance on a single-source supplier for medical-grade silicone is a common practice in the industry, but it poses a risk to its supply chain.

Related Party Transactions

• The company recorded revenue of $1.0 million for product sales to Herramientas Medicas, S.A., a distribution company owned by a family member of the Chief Executive Officer.
• The company paid Dr. Chacn Quirs, the brother of the company's Chief Executive Officer, approximately $0.2 million for training services.
• The company granted Nicholas Lewin, a member of the board of directors, a stock option award for 7,829 options and a performance-based grant for 27,756 restricted stock units as compensation for consulting services.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and continued losses.
• Employees may be affected by the company's cost management measures, including headcount reductions.
• Customers in the U.S. will now have access to Motiva Implants.
• Suppliers may be impacted by changes in the company's manufacturing and supply chain.
• Creditors may be concerned about the company's debt levels and ability to repay its obligations.

Next Steps

• The company will focus on commercializing Motiva Implants in the United States.
• The company will continue to manage operating expenses.
• The company will continue to monitor the market and adjust its strategies as needed.
• The company will continue to work on remediating the material weakness in internal control over financial reporting.

Key Dates

Keywords

Motiva Implants, FDA approval, breast implants, medical devices, manufacturing, revenue, net loss, clinical trials, regulatory approval, silicone, capital raise, financial results